Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials

Antonio Facciorusso, Mohamed A Abd El Aziz, Nicola Tartaglia, Daryl Ramai, Babu P Mohan, Christian Cotsoglou, Sara Pusceddu, Luca Giacomelli, Antonio Ambrosi, Rodolfo Sacco, Antonio Facciorusso, Mohamed A Abd El Aziz, Nicola Tartaglia, Daryl Ramai, Babu P Mohan, Christian Cotsoglou, Sara Pusceddu, Luca Giacomelli, Antonio Ambrosi, Rodolfo Sacco

Abstract

There are limited and discordant results on the comparison between microwave ablation (MWA) and radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC). This meta-analysis aims to compare the two treatments in terms of efficacy and safety, based on a meta-analysis of randomized-controlled trials (RCTs). A computerized bibliographic search was performed on the main databases throughout August 2020. The primary outcome was the complete response rate, while survival rate (at 1-, 2-, 3-, and 5-year), disease-free survival rate (at 1-, 2-, 3-, and 5-year), local and distant recurrence rate, adverse event rate, and number of treatment sessions were the secondary outcomes. Seven RCTs enrolling 921 patients were included. No difference in terms of complete response between the two treatments was observed (risk ratio (RR) 1.01, 95% CI 0.99-1.02). Survival rates were constantly similar, with RRs ranging from 1.05 (0.96-1.15) at 1 year to 0.91 (0.81-1.03) at 5 years. While local recurrence rate was similar between MWA and RFA (RR 0.70, 0.43-1.14), distant recurrence rate was significantly lower with MWA (RR 0.60, 0.39-0.92). Disease-free survival at 1, 2, and 3 years was similar between the two groups with RR 1.00 (0.96-1.04), 0.94 (0.84-1.06), and 1.06 (0.93-1.21), respectively. On the other hand, RR for disease-free survival at 5 years was significantly in favor of MWA (3.66, 1.32-42.27). Adverse event rate was similar between the two treatments (RR 1.06, 0.48-2.34), with bleeding and hematoma representing the most frequent complications. Our results indicate a similar efficacy and safety profile between the two techniques. MWA seems to decrease the rate of long-term recurrences, but this finding needs to be confirmed in further trials.

Keywords: HCC; MWA; RFA; liver cancer; recurrence; survival.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the search strategy.
Figure 2
Figure 2
Risk ratio concerning the comparison between microwave and radiofrequency ablation in terms of complete response was 1.01 (95% confidence interval 0.99–1.02), with no evidence of heterogeneity (I2 = 0%).

References

    1. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011;365:1118–1127. doi: 10.1056/NEJMra1001683.
    1. Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J. Gastroenterol. 2018;24:161–169. doi: 10.3748/wjg.v24.i2.161.
    1. Facciorusso A., Serviddio G., Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. World J. Gastrointest. Pharmacol. Ther. 2016;7:477–489. doi: 10.4292/wjgpt.v7.i4.477.
    1. Facciorusso A., El Aziz M.A.A., Cincione I., Cea U.V., Germini A., Granieri S., Cotsoglou C., Sacco R. Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study. Biomedicines. 2020;8:399. doi: 10.3390/biomedicines8100399.
    1. Pompili M., Saviano A., De Matthaeis N., Cucchetti A., Ardito F., Federico B., Brunello F., Pinna A.D., Giorgio A., Giulini S.M., et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3cm. Results of a multicenter Italian survey. J. Hepatol. 2013;59:89–97. doi: 10.1016/j.jhep.2013.03.009.
    1. Majumdar A., Roccarina D., Thorburn D., Davidson B., Tsochatzis E., Gurusamy K. Management of people with early or very early stage hepatocellular carcinoma: An attempted network meta-analysis. J. Hepatol. 2017;66:S214. doi: 10.1016/S0168-8278(17)30726-2.
    1. Facciorusso A., Del Prete V., Antonino M., Crucinio N., Neve V., Di Leo A., Carr B.I., Barone M. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. Dig. Liver Dis. 2014;46:1014–1019. doi: 10.1016/j.dld.2014.07.012.
    1. Facciorusso A., Del Prete V., Antonino M., Neve V., Amoruso A., Crucinio N., Di Leo A., Barone M. Conditional survival analysis of hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatol. Res. 2015;45:E62–E72. doi: 10.1111/hepr.12458.
    1. Facciorusso A., Del Prete V., Antonino M., Neve V., Crucinio N., Di Leo A., Carr B.I., Barone M. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J. Gastroenterol. Hepatol. 2014;29:1905–1910. doi: 10.1111/jgh.12618.
    1. Ricci A.D., Rizzo A., Bonucci C., Tavolari S., Palloni A., Frega G., Mollica V., Tober N., Mazzotta E., Felicani C., et al. The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. In Vivo. 2020;34:3421–3429. doi: 10.21873/invivo.12181.
    1. Bruix J., Takayama T., Mazzaferro V., Chau G.-Y., Yang J., Kudo M., Cai J., Poon R.T., Han K.-H., Tak W.Y., et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354. doi: 10.1016/S1470-2045(15)00198-9.
    1. Facciorusso A., Muscatiello N., Di Leo A., Barone M. Combination Therapy With Sorafenib and Radiofrequency Ablation for Hepatocellular Carcinoma: A Glimmer of Light after the Storm Trial? Am. J. Gastroenterol. 2015;110:770–771. doi: 10.1038/ajg.2015.80.
    1. Facciorusso A., Di Maso M., Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Int. J. Hyperth. 2016;32:339–344. doi: 10.3109/02656736.2015.1127434.
    1. Meijerink M.R., Puijk R.S., Van Tilborg A.A.J.M., Henningsen K.H., Fernandez L.G., Neyt M., Heymans J., Frankema J.S., De Jong K.P., Richel D.J., et al. Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Cardiovasc. Interv. Radiol. 2018;41:1189–1204. doi: 10.1007/s00270-018-1959-3.
    1. Luo W., Zhang Y., He G., Yu M., Zheng M., Liu L., Zhou X. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: A systematic review and meta-analysis. World J. Surg. Oncol. 2017;15:126. doi: 10.1186/s12957-017-1196-2.
    1. Weis S., Franke A., Mössner J., Jakobsen J.C., Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst. Rev. 2013:CD003046. doi: 10.1002/14651858.CD003046.pub3.
    1. Cui R., Yu J., Kuang M., Duan F., Liang P. Microwave ablation versus other interventions for hepatocellular carcinoma: A systematic review and meta-analysis. J. Cancer Res. Ther. 2020;16:379–386. doi: 10.4103/jcrt.jcrt_403_19.
    1. Abdelaziz A., Elbaz T., Shousha H.I., Mahmoud S., Ibrahim M., Abdelmaksoud A., Nabeel M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: An egyptian multidisciplinary clinic experience. Surg. Endosc. 2014;28:3429–3434. doi: 10.1007/s00464-014-3617-4.
    1. Chong C., Lee K.F., Cheung S.Y., Chu C.C., Fong A.K., Wong J., Hui J.W., Fung A.K., Lok H.T., Lo E.Y., et al. Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial) HPB. 2020;22:1121–1127. doi: 10.1016/j.hpb.2020.01.008.
    1. Kamal A., Elmoety A.A.A., Rostom Y.A.M., Shater M.S., Lashen S.A. Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: A randomized controlled trial. J. Gastrointest. Oncol. 2019;10:562–571. doi: 10.21037/jgo.2019.01.34.
    1. Qian G.-J., Wang N., Shen Q., Sheng Y.H., Zhao J.-Q., Kuang M., Liu G.-J., Wu M.-C. Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: Experimental and clinical studies. Eur. Radiol. 2012;22:1983–1990. doi: 10.1007/s00330-012-2442-1.
    1. Shibata T., Iimuro Y., Yamamoto Y., Maetani Y., Ametani F., Itoh K., Konishi J. Small Hepatocellular Carcinoma: Comparison of Radio-frequency Ablation and Percutaneous Microwave Coagulation Therapy. Radiology. 2002;223:331–337. doi: 10.1148/radiol.2232010775.
    1. Violi N.V., Duran R., Guiu B., Cercueil J.-P., Aubé C., Digklia A., Pache I., Deltenre P., Knebel J.-F., Denys A. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: A randomised controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 2018;3:317–325. doi: 10.1016/S2468-1253(18)30029-3.
    1. Yu J., Yu X.-L., Han Z.-Y., Cheng Z.-G., Liu F.-Y., Zhai H.-Y., Mu M.-J., Liu Y.-M., Liang P. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase III randomised controlled trial. Gut. 2017;66:1172–1173. doi: 10.1136/gutjnl-2016-312629.
    1. Glassberg M.B., Ghosh S., Clymer J.W., Qadeer R.A., Ferko N., Sadeghirad B., Wright G.W., Amaral J.F. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: A systematic review and meta-analysis. OncoTargets Ther. 2019;12:6407–6438. doi: 10.2147/OTT.S204340.
    1. Tan W., Deng Q., Lin S., Wang Y., Xu G. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: A systematic review and meta-analysis. Int. J. Hyperth. 2019;36:263–271. doi: 10.1080/02656736.2018.1562571.
    1. Hutton B., Salanti G., Caldwell D.M., Chaimani A., Schmid C.H., Cameron C., Ioannidis J.P.A., Straus S., Thorlund K., Jansen J.P., et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann. Intern. Med. 2015;162:777–784. doi: 10.7326/M14-2385.
    1. Higgins J.P., Altman D.G., Gøtzsche P.C., Jüni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.
    1. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2.
    1. Metafor: Meta-Analysis Package for R. [(accessed on 24 August 2020)]; Available online: .

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj